Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 03, 2021

SELL
$48.48 - $78.23 $4.76 Million - $7.68 Million
-98,130 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$50.3 - $78.44 $4.94 Million - $7.7 Million
98,130 New
98,130 $7.7 Million
Q1 2021

May 12, 2021

SELL
$53.8 - $81.53 $3.77 Million - $5.71 Million
-70,015 Closed
0 $0
Q4 2020

Feb 10, 2021

SELL
$36.89 - $93.56 $3 Million - $7.6 Million
-81,275 Reduced 53.72%
70,015 $5.86 Million
Q3 2020

Nov 05, 2020

BUY
$23.13 - $38.84 $3.5 Million - $5.88 Million
151,290 New
151,290 $5.42 Million
Q2 2019

Aug 05, 2019

SELL
$18.5 - $28.14 $1.36 Million - $2.07 Million
-73,605 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$17.99 - $24.65 $1.32 Million - $1.81 Million
73,605 New
73,605 $1.71 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.9B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Lisanti Capital Growth, LLC Portfolio

Follow Lisanti Capital Growth, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lisanti Capital Growth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lisanti Capital Growth, LLC with notifications on news.